2. Apoptosis
  3. RIP kinase Necroptosis
  4. RIP1-IN-1

RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM). RIP1-IN-1 exhibits strong anti¬-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury.

For research use only. We do not sell to patients.

RIP1-IN-1 Chemical Structure

RIP1-IN-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

RIP1-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All RIP kinase Isoform Specific Products:

View All Isoforms
RIPK1 RIPK2 RIPK3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM). RIP1-IN-1 exhibits strong anti¬-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury[1].

IC50 & Target[1]

RIPK1

110 nM (Kd)

In Vitro

RIP1-IN-1 (Compound N-1) (0-1.6 μM, 5-24 h) can effectively and dose-dependently inhibit Z-VAD-FMK (HY-16658B) induced necroptosis in HT-29 cells, as well as Z-VAD-FMK (HY-16658B) induced necroptosis in U937 cells[1].
RIP1-IN-1 exhibits strong anti-necroptosis activity in HT-29 cells (CC50: >50 μM EC50: 8.8 nM)[1].
RIP1-IN-1 (0.4 μM, 2-6 h) effectively prevents the phosphorylation of both RIP1 and RIP3 in HT-29 cells treated with Z-VAD-FMK (HY-16658B) in a time-dependent manner, thereby inhibiting the phosphorylation of the downstream target MLKL[1].
RIP1-IN-1 (0.097-400 nM, 5 h) inhibits RIP1/3 and MLKL phosphorylation in a dose-responsive manner[1].
RIP1-IN-1 (400 nM, 6 h) inhibits Z-VAD-FMK (HY-16658B) induced necrosome formation in HT-29 cells by blocking phosphorylation of the RIP1/RIP3/MLKL pathway, demonstrating its anti-necroptosis activity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RIP1-IN-1 Related Antibodies

Western Blot Analysis[1]

Cell Line: TSZ (30 μM) treated HT-29 cells
Concentration: 0.097、1.562、25、400 nM
Incubation Time: 2-6 h
Result: Prevented the phosphorylation of both RIP1 and RIP3 within 2-6 h and subsequently inhibited downstream target MLKL phosphorylation.
Reduced pRIP1, pRIP3, and pMLKL levels in a dose-dependent manner in the range of 0.097-400 nM.
Parmacokinetics[1]
Species Dose Route Indicator value
Rat 10 mg/kg i.g. T1/2 0.82 hr
Rat 10 mg/kg i.g. Tmax 0.5 hr
Rat 10 mg/kg i.g. Cmax 726 ng/mL
Rat 10 mg/kg i.g. MRT 1.65 hr
Rat 10 mg/kg i.g. CL/F 116 mL/min/kg
Rat 10 mg/kg i.g. Vd/F 8.29 L/kg
Rat 10 mg/kg i.g. AUC0-t 1.442 μg·h/mL
Rat 10 mg/kg i.g. AUC0-inf 1.449 μg·h/mL
Rat 10 mg/kg i.g. F 26.3 %
In Vivo

RIP1-IN-1 (Compound N-1) (1,3,5 mg/kg, p.o.) shows anti-necroptosis effects in SIRS (systemic inflammatory response syndrome) mice[1].
RIP1-IN-1 (3 mg/kg, i.g. once a day for 14 consecutive days) shows protective effect in the CCl4-induced acute liver injury model in mice[1].
RIP1-IN-1 (10 mg/kg, i.g.) shows short half-life and high clearance in Sprague-Dawley rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice; Establishment of SIRS mice model by combining mTNF-α (65 μg/kg) and Z-VAD-FMK (200 μg/piece)[1]
Dosage: 1, 3, 5 mg/kg (5 % DMSO and 95 % CMC-Na solution)
Administration: p.o.
Result: Significantly improved the survival rate of SIRS mice, reaching 20%, 50% and 90%.
Alleviated mTNF-α-induced hypothermia within 9 hours.
Significantly reduced serum IL-6 levels, indicating its anti-inflammatory effect.
Animal Model: Male ICR mice (6–8 weeks old), 0.01 % CCl4induced acute liver injury mice model[1]
Dosage: 1, 3, 5 mg/kg (5 % DMSO and 95 % CMC-Na solution)
Administration: i.g., once daily for 14 consecutive days
Result: Significantly reduced RIP1, RIP3, and MLKL phosphorylation in diseased mice, thereby restoring AST and ALT markers indicative of liver damage.
HE staining showed that the liver tissue structure was close to normal at a dose of 3mg/kg and 5mg/kg, and the damage was significantly reduced.
The result showed that ALT, AST, and IL-6 levels were significantly reduced and close to the normal range, indicating that it can play a protective role against acute liver damage.
Western Blot results showed that it can effectively inhibit phosphorylation and block the necroptosis pathway.
Molecular Weight

423.46

Formula

C26H21N3O3
SMILES

CN1C2=CC=CC=C2OC[C@H](NC(C3=CC(C(C4=CC=CC=C4)=CC=N5)=C5C=C3)=O)C1=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

RIP1-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RIP1-IN-1RIP kinaseNecroptosisReceptor-interacting protein kinasesRIPKRIP1 inhibitoracute liver injurySIRSphosphorylation inhibitionRIP1/RIP3/MLKL pathwayInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
RIP1-IN-1
Cat. No.:
HY-173185
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.